Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GAO report finds little evidence supporting pharmacy-only class of drugs.

This article was originally published in The Tan Sheet

Executive Summary

GAO FINDS THIRD CLASS OF DRUGS NOT SUPPORTED BY AVAILABLE EVIDENCE in a report released Aug. 24. At the request of Rep. John Dingell (D-Mich.) in 1992, GAO conducted an assessment of "the evidence for creating an additional class of drugs in the U.S. that would not be for sale outside pharmacies but would be available without a physician's prescription." The report concludes that "little evidence supports the establishment of a pharmacy or pharmacist class of drugs in the U.S. at this time."

You may also be interested in...



Third Class Of Drugs Should Not Be “Completely Closed Down” – Ganley

Debate on the merits of a third class of drugs could resurface as FDA considers Rx-to-OTC switch applications of drugs indicated for chronic conditions

Third Class Of Drugs Should Not Be “Completely Closed Down” – Ganley

Debate on the merits of a third class of drugs could resurface as FDA considers Rx-to-OTC switch applications of drugs indicated for chronic conditions

Third Class Of Drugs Should Not Be “Completely Closed Down” – Ganley

Debate on the merits of a third class of drugs could resurface as FDA considers Rx-to-OTC switch applications of drugs indicated for chronic conditions

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel